Public Companies
Wellbeing Digital to Participate at this Years’ Wonderland Miami Conference
Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation…
Wellbeing Digital Sciences Inc. (NEO: MEDI | OTC: KONEF | (FRA: SQ2), an evidence-based mental healthcare company focused on the development and implementation of innovative clinical solutions, including psychedelic medicine and digital therapeutics as supported by clinical research, announces that Najla Guthrie, CEO, will participate at this years’ Wonderland Miami Conference taking place on November 3 to November 5, 2022 at the Mana Wynwood Convention Centre.
Wonderland is one of the world’s largest conferences in the psychedelic medicine sector. It provides an opportunity to discover the world of psychedelic medicine, and is attended by some of the leading founders, investors, therapists, practitioners, researchers, thought leaders, innovators, and media from around the globe.
Najla Guthrie will participate on 3 panels:
November 4 at 9:30 a.m. ET- The Politics of Psychedelic Medicine – Will the evidence from psychedelic medicine research move politicians to develop a more rational and progressive drug policy?
November 4 at 5:00 p.m. ET- Building the Last Mile – Building centers of excellence for next generation therapies.
November 5 at 12:20 p.m. ET- Ketamine for Pain & Depression from Randomized Clinical Trials to Real Life Evidence – What does the current data show for using ketamine for pain and depression? The panel will explore how to connect trial results with personalized ketamine treatments.
Register to attend here.
For more information about the conference, or to schedule a one-on-one meeting with Wellbeing management team, please send an email to Natalie Dolphin at ndolphin@wellbeingdigital.co.
About Wellbeing Digital Sciences
Wellbeing Digital Sciences Inc. is an evidence-based mental healthcare company focused on the development and implementation of innovative clinical treatment solutions, including psychedelic medicine and digital therapeutics, as supported by clinical research. Its mission is supported by a network of North American clinics that provide forward-thinking therapies and other types of treatment to patients as well as through a contract research organization that offers clinical trials services to clients pursuing drug development.
-
Psychedelics1 week ago
Algernon NeuroScience and the Centre for Human Drug Research to Present DMT Phase 1 Stroke Clinical Data at the Interdisciplinary Conference on Psychedelic Research June 6 – 8th, 2024
-
Psychedelics1 week ago
Revive Therapeutics Announces Type C Meeting Request Granted by FDA for Clinical Study of Bucillamine to Treat Long COVID
-
Psilocybin1 week ago
Passover Perspectives: Psychedelics, Moses, and the Burning Bush
-
Law & Regulation1 week ago
Tryp Therapeutics merger with Exopharm approved by shareholders
-
Psychedelics1 week ago
atai Life Sciences Announces Dosing of First Patient in Part 2 of Beckley Psytech’s Phase 2a Study Exploring BPL-003 Adjunctive to SSRIs in Patients with Treatment Resistant Depression
-
Psychedelics1 week ago
Silo Pharma Announces Positive Results for Intranasal PTSD Treatment
-
Psilocybin1 week ago
Psilocybin and Meditation: Unlocking the Potential for Enhancing Insightfulness
-
Psychedelics1 week ago
Optimi Health and Kwantlen Polytechnic University Applied Genomics Centre Partner to Advance Mushroom Science and Research